Eli Lilly Isn't Replacing Zepbound -- It's Building an Obesity Empire
Eli Lilly is building an obesity empire by adding retatrutide and the oral GLP‑1 pill Foundayo to its Zepbound franchise. Retatrutide delivered a 28.7% mean weight loss in a 68‑week Phase 3 trial, outpacing Zepbound’s 20.2% result. The company is targeting the severe‑obesity segment—about 22 million U.S. adults—representing a $66 billion market that could generate $13‑$19 billion for retatrutide alone. Analysts see a medium‑term tailwind, though competition and a lower ranking by Motley Fool temper enthusiasm.
Letrozole Monotherapy Falls Short in Ovarian Cancer Clinical Trial
The phase III NRG GY019 trial showed that letrozole monotherapy did not meet the non‑inferiority endpoint for progression‑free survival compared with the standard paclitaxel‑carboplatin followed by letrozole regimen in newly diagnosed low‑grade serous ovarian carcinoma. At a median 27.3‑month follow‑up, the hazard...
Nanodisc Technology Improves Study of Viral Proteins for Vaccines
Scientists at Scripps Research, in partnership with IAVI, have unveiled a nanodisc‑based platform that embeds viral surface proteins in lipid‑like particles, preserving their native membrane context. Published in Nature Communications, the method was validated with HIV and Ebola glycoproteins, delivering...
Mezagitamab Shows Promise in Treating Immune Thrombocytopenia Patients
Mezagitamab, an anti‑CD38 antibody originally developed for oncology, achieved a 91% platelet‑response rate in a phase 2 trial of patients with immune thrombocytopenia (ITP). In the 600 mg cohort, 10 of 11 participants reached the predefined platelet count threshold within 16 weeks,...
New Project Aims to Improve Aggressive Breast Cancer Diagnosis
The BRIDGE project, a two‑year collaboration between ITQB NOVA and the Portuguese Institute of Oncology, aims to discover glyco‑immune biomarkers that signal aggressive breast cancer progression. By analyzing small molecules on tumor‑cell surfaces, researchers hope to map how cancers silence the...
America Has a New GLP-1 Playbook
The latest GLP‑1 oral formulations—Eli Lilly’s Foundayo and Novo Nordisk’s Wegovy pill—offer a needle‑free alternative but deliver modest weight‑loss results compared with their injectable counterparts. Clinical data show Foundayo can preserve most of the weight lost on injections over a year, while...
More Pharma Dealmaking; FDA’s Proposed Budget; Takeda Ends Partnership; and More
The pharma sector is seeing a wave of dealmaking, with Q1 2026 M&A volume up roughly 15% as companies chase high‑value oncology assets. The FDA released a proposed $5.6 billion budget that would raise review fees by about 8% and modestly...
20 Future Hungarian HealthTech and MedTech Leaders
Hungary’s health‑tech and med‑tech ecosystem is maturing into a deep‑tech hub, backed by more than €925 million (≈ $1 billion) of venture capital between 2015‑2025. State agencies, university‑owned technology transfer companies and accelerators have built a supportive pipeline that channeled €41.2 million (≈ $44.5 million) in...
Effects of Glucagon-Like Peptide-1 Receptor Agonists on Perioperative Outcomes in Hip and Knee Arthroplasty: A Systematic Review and Meta-Analysis
Researchers performed a systematic review and meta‑analysis of six retrospective cohort studies covering over 48,000 hip and knee arthroplasty patients to assess the impact of pre‑operative glucagon‑like‑peptide‑1 receptor agonist (GLP‑1 RA) therapy. The analysis found a 20 % reduction in revision...
Re: The Power of the Markets: The Scandal that Keeps on Taking
Lenacapavir, a once‑monthly injectable for HIV, is priced at $28,000 per patient annually by Gilead Sciences. In a BMJ rapid response, surgeon Simon Bell argued the price reflects the high cost of drug development and that Gilead is not obligated...
AI Can Screen 15 Million Molecules in a Day. It Still Can’t Cure Alzheimer’s.
Novartis used generative AI to design 15 million molecular‑glue candidates for Huntington’s disease and synthesized about 60, yielding a promising scaffold. While AI can trim early‑stage drug discovery timelines by 30‑40 percent and lower costs, no AI‑discovered compound has secured FDA approval...
New Yellow Fever Vaccine Matches Safety and Effectiveness of Current Shot
Sanofi's new live‑attenuated yellow fever vaccine, vYF, demonstrated safety and efficacy comparable to the licensed YF‑VAX in a phase 2 trial of 485 healthy adults. Protective antibodies appeared in 99.7% of vYF recipients versus 99.4% for YF‑VAX within 28 days, with...
EV-RNAs Show Promise for IBD Diagnosis and Treatment
A review in *ExRNA* led by Professor Xiyang Wei outlines how extracellular vesicle‑associated RNAs (EV‑RNAs) influence inflammatory bowel disease (IBD) pathogenesis and progression. By synthesizing multi‑omics and animal data, the authors show EV‑RNAs can serve as highly accurate, non‑invasive biomarkers...
Insilico Medicine Launches Pharma AI Spring Kickoff 2026 Webinar
Insilico Medicine announced the Pharma.AI Spring Kickoff 2026 webinar for April 14, 2026, at 10:00 AM ET. The event will showcase the company’s latest AI-driven drug discovery tools, including the MMAI Gym training framework, upgraded PandaOmics with single‑cell integration, and new capabilities in...
Big Pharma Is Turning to China for the Newest Drug Ideas
Pfizer is intensifying its search for breakthrough cancer treatments by tapping Chinese biotech. Last summer the company paid $1.25 billion to Shanghai‑based 3SBio for rights to a promising oncology candidate. The move reflects a broader shift as China evolves from a...
Nanomedicine Offers Targeted Solutions for Breast Cancer Treatment
Nanomedicine is reshaping breast cancer therapy by using nanoscale carriers to improve drug solubility, targeting, and controlled release. Recent preclinical studies show lipid‑polymer hybrids boosting oral bioavailability over threefold and photothermal nanoparticles halving tumor growth when combined with chemotherapy. Metallic...
Pyrazole-Derived TRPC3 Antagonist Ameliorates Synaptic Dysfunctions and Memory Deficits in Alzheimer’s Disease Models
Researchers have engineered a pyrazole‑derived, metabolically stable TRPC3 antagonist that readily penetrates the CNS. In cultured neurons, amyloid‑beta oligomers up‑regulate TRPC3, leading to calcium overload and toxicity. Administration of the compound to 5xFAD and APPKI mouse models reversed synaptic deficits...
Multi-Omics and Electrophysiological Examination of GABAA Receptors in the Dorsolateral Prefrontal Cortex of Humans with Alcohol Use Disorder
Researchers recorded electrophysiological activity of reactivated GABA_A receptors from the dorsolateral prefrontal cortex of postmortem brains of individuals with alcohol use disorder (AUD). Multi‑omics analysis revealed significantly lower mRNA levels for several GABA_A subunits, yet protein abundance and synaptic function...
Australia: Ingestible Smart Sensor Boosts Non-Invasive Diagnostics
A world‑first ingestible gas‑sensing capsule, developed from RMIT University research, has been commercialised in Victoria, offering clinicians a radiation‑free, real‑time view of the gastrointestinal tract. The device moves beyond invasive procedures, targeting the roughly 40% of people who suffer from...
Reprogramming Regulatory T Cells Could Help Immunotherapy Work in Pancreatic Cancer
Researchers at Oregon Health & Science University discovered that pancreatic tumors suppress immunotherapy by recruiting large numbers of regulatory T cells (Tregs). In mouse models, an agonistic CD40 therapy not only activated tumor‑killing immune cells but also reprogrammed Tregs into...
Trinity Launches InsightsEDGE™ | Digital Twins — Generative AI Unlocks Always-On Intelligence for Life Sciences Commercial Teams
Trinity has launched InsightsEDGE™ | Digital Twins, an AI‑driven solution that builds interactive virtual replicas of healthcare professionals, patients and payers using real‑world data. The tool extends the company’s existing InsightsEDGE platform, turning one‑off research into a continuously refreshed, always‑on...
Fibrosis Company Avalyn Seeks NASDAQ Listing Amid Volatility: Finance Report
Avalyn Pharma, a Boston biotech focused on inhaled treatments for pulmonary fibrosis, filed a prospectus to list on NASDAQ despite ongoing market volatility. The company’s pipeline includes two Phase II programs: AP01, an inhaled pirfenidone in the Phase IIb MIST trial, and...
Scientists Successfully Made Advanced, Lab-Grown Brains—Could They Become Conscious?
Scientists have advanced brain organoid technology by connecting miniature brain tissue to prototype spinal cords, creating a four‑part assembloid that mimics the human pain‑sensory pathway. Despite this complexity, the structures contain just 0.002% of the neurons found in a full...
Finerenone Reduces Clinical Events in Patients With Heart Failure Regardless of CHD History
A prespecified analysis of the FINEARTS‑HF trial evaluated finerenone in 6,001 patients with heart‑failure with mildly reduced or preserved ejection fraction, 54% of whom had a history of coronary heart disease. Finerenone reduced the composite of cardiovascular death and heart‑failure...
Devyser Partners with Illumina
Devyser announced a strategic partnership with Illumina that will pair selected Illumina sequencing platforms with Devyser’s proprietary reagent kits. Under the agreement, Devyser’s customers can obtain the sequencers through a reagent‑commitment model rather than a traditional capital purchase. The collaboration...
Predictors of Rapid, Complete Skin Clearance With Psoriasis Biologics
A real‑world analysis of 299 moderate‑to‑severe psoriasis patients treated with biologics found that 76.3% achieved an early super‑response (PASI 100 by week 4 and maintained PASI < 1 through week 48). The strongest positive predictors were biologic‑naïve status and higher baseline neutrophil counts, while palmoplantar...
First Detailed Insight Into Bornavirus Nucleoprotein–RNA Complex Reveals Unique Assembly
Researchers from Kyoto, Osaka Dental, and Osaka Metropolitan Universities used cryo‑electron microscopy to obtain the first high‑resolution structure of the Borna disease virus 1 (BoDV‑1) nucleoprotein‑RNA complex. The study revealed ring‑like assemblies where each nucleoprotein subunit binds eight RNA nucleotides,...
Lung Cancer Molecular Testing Nears 70%, Still Falls Short of Universal Use: Christopher D'Avella, MD
Molecular profiling for newly diagnosed advanced non‑small cell lung cancer has risen from about 50% to roughly 70% before first‑line therapy, driven by stronger guideline awareness and more targetable mutations. However, testing gaps persist, especially when biopsies are performed without...
PreCheck Pilot Program Structure
The FDA’s PreCheck Pilot Program introduces a two‑phase pathway to speed the launch of new U.S. pharmaceutical manufacturing sites. Phase 1 delivers early, structured Pre‑Operational Reviews (POR) and builds a Type V Drug Master File that captures facility design, equipment qualification, and...
Oricell Therapeutics Secures $110 Million to Take on One of Oncology's Most Vexing Problems
Oricell Therapeutics closed a pre‑IPO financing round exceeding $110 million, led by Vivo Capital and a slate of international investors. The capital will fund global clinical expansion and further development of its proprietary CAR‑T platform targeting solid tumors. Oricell’s lead candidate,...
University of Cincinnati Launches Clinical Trial to Test New Drug for Prosthetic Joint Infections
The University of Cincinnati has begun enrolling patients in Peptilogics' RETAIN trial, a randomized, double‑blind study evaluating a novel peptide solution designed to penetrate biofilm in prosthetic joint infections (PJI). The trial will compare the peptide irrigant against a saline...
Cryo-EM Structural Biology Facility Opened in San Diego by FairJourney Bio
FairJourney Bio has launched an advanced cryo‑electron microscopy (cryo‑EM) structural biology facility in San Diego, featuring two 300 kV ThermoFisher Titan Krios 5 systems. The lab brings atomic‑resolution imaging directly into the company’s antibody discovery platform, supporting everything from epitope mapping to...
Plan for Remade ACIP Panel Adds Focus on Vaccine Safety, Matching Kennedy’s Push
A federal judge recently halted most Trump-era appointments to the CDC’s Advisory Committee on Immunization Practices (ACIP), prompting the agency to draft a new charter that reshapes the panel’s composition and priorities. The revised charter emphasizes vaccine safety, mandating transparent...
5 Vaccines Under Development That Would Change the World As We Know It
Recent advances in vaccine technology are targeting five of the world’s most persistent health threats: HIV, tuberculosis, cancer, influenza, and coronaviruses. Early-phase trials show mRNA‑based germline‑targeting approaches can induce broadly neutralizing antibodies against HIV, while the M72/AS01E candidate achieved roughly...
FDA Clears Investigational New Drug Application to Test sCAR-T Therapy for Autoimmune Conditions
The FDA has cleared Calibr‑Skaggs Institute’s investigational new drug application to test its switchable CAR‑T therapy, CLBR001 + SWI019, in a phase 1 trial for autoimmune diseases. The study will enroll patients with myositis, systemic sclerosis, lupus and rheumatoid arthritis, aiming to demonstrate...
Bioanalytical Method Validation for Biomarkers
The U.S. Food and Drug Administration issued final Level 2 guidance (Docket FDA‑2017‑D‑6821) on bioanalytical method validation for biomarkers. It outlines the evidentiary standards for measuring biomarker concentrations in clinical trials and non‑clinical studies. The guidance applies to IND, NDA, BLA, ANDA,...
Alpheus Medical Advances to Phase 2b Testing of Experimental Brain Cancer Therapy
Alpheus Medical has enrolled 10 patients in a Phase 2b randomized trial of its Porphyrin Metabolite Activation (PoMA) therapy for newly diagnosed glioblastoma. PoMA uses a tumor‑selective drug activated by low‑intensity diffuse ultrasound to treat the entire affected brain hemisphere,...
Replimune’s Advanced Melanoma Drug Rebuffed by FDA for Second Time
Replimune’s oncolytic immunotherapy RP1, aimed at unresectable advanced cutaneous melanoma, was rejected by the FDA for a second time on April 6, 2026. The agency’s complete response letter said the data, derived from a single‑arm trial, were insufficient to demonstrate substantial effectiveness,...
This Startup Is Using Blood Samples to Transform Depression Treatment
NeuroKaire, a startup founded by neuroscientists Dr. Talia Cohen Solal and Dr. Daphna Laifenfeld, has launched BrightKaire, a precision‑psychiatry test that uses a simple blood draw to predict individual responses to antidepressants. The test creates patient‑specific neurons in a dish, exposes...
BMS and Oxford BioTherapeutics Join Forces in TCE Discovery Pact
Bristol Myers Squibb has entered a discovery partnership with Oxford BioTherapeutics to develop T‑cell engager (TCE) therapies for solid tumours. BMS will pay an undisclosed upfront fee to access OBT’s OGAP‑Verify platform, while OBT will design and deliver pre‑clinical candidates....
Bacteria From Bumblebees Can Produce Vitamin B₂ in Soya Drinks
Researchers at Denmark's Technical University (DTU) used a droplet microfluidics platform to screen the bumblebee gut microbiome, identifying a Lactococcus lactis strain that ferments soy drinks while producing vitamin B₂. The transparent soy medium and fluorescence‑based detection cut screening time from...
Drugs From a Text Prompt, Wegovy Pill Competition Dampens Lilly’s Surge
Agentic AI is revolutionizing drug discovery, allowing scientists to generate candidates from simple text prompts and run extended‑reality guided experiments. In parallel, Gilead announced a deal to acquire Tubulis for up to $5 billion, strengthening its antibody‑drug conjugate portfolio. Eli Lilly and...
Other News to Note for April 10, 2026
BioWorld’s April 10 briefing highlights three notable developments. Jiangsu and Shanghai Hengrui have patented novel Nav1.8 sodium‑channel blockers, a class of compounds with potential for pain and inflammatory disease therapies. New hematopoietic stem‑cell research links chronic inflammation to early‑stage leukemia, deepening...
China Biotech’s CRISPR Therapy Suggests US Drugmakers Will Face Competition
A Chinese biotech firm used CRISPR‑Cas9 to edit blood stem cells in five beta thalassemia patients, eliminating their need for regular transfusions. The ex‑vivo therapy reactivates fetal hemoglobin and showed durable engraftment with no serious adverse events over a year...
Using Menstrual Blood-Derived Particles to Treat Osteoarthritis
Lithuanian researchers have demonstrated that extracellular vesicles (EVs) harvested from menstrual‑blood‑derived mesenchymal stromal cells can stimulate cartilage regeneration in vitro, offering a cell‑free therapy for osteoarthritis. The EVs improved chondrocyte function and extracellular matrix synthesis even in cartilage cells taken...
Blackstone’s Galakatos on Scaling Deals with $6.3B Fund: ‘Broader, Further’
Blackstone’s Galakatos team announced a new $6.3 billion private‑equity fund aimed at scaling the number and size of its transactions. The fund will pursue a broader geographic footprint and deeper sector coverage, focusing on later‑stage growth and buy‑and‑build opportunities. Galakatos plans...
Oricell Closes a ‘Pre-IPO’ Megaround to Aim CAR-T at Solid Tumors
Oricell Therapeutics, a Shanghai‑based biotech, closed a pre‑IPO financing round of more than $110 million to accelerate its CAR‑T programs targeting solid tumors, starting with liver cancer. Its lead candidate, Ori‑C101, targets the GPC3 protein and has shown a 60% response...
Vivatides Gets $54M; Wegovy Drops Cold Chain in EU; Gilead Takes Kymera Option
Vivatides Therapeutics announced a $54 million Series A round to accelerate its pre‑clinical siRNA and antisense oligonucleotide programs, with Sequoia Capital leading the investment. In Europe, Novo Nordisk confirmed that its obesity drug Wegovy will drop the costly cold‑chain requirement, simplifying distribution. Meanwhile,...
FDA/Center for Research on Complex Generics (CRCG) Workshop on Bioequivalence Innovations for Generic Oral Products: Biowaivers, Bridging, and Development for...
On May 5‑6, 2026, the FDA’s Center for Research on Complex Generics hosted a two‑day workshop in Rockville, MD to explore innovative bioequivalence (BE) strategies for generic oral drugs. The agenda covered biowaivers, bridging studies, and development pathways for oncology agents,...
Biotech VCs Ramp up Checks on New Bets After Years of Focusing on Existing Portfolios
Biotech venture capitalists are shifting back to high‑risk, high‑reward investing, with 65% of Q1 2026 capital directed at new startups. Total venture funding in the sector rose to roughly $2.1 billion, up from $1.5 billion a quarter earlier, and average deal size climbed...
